BCRX Q4 2017 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-56.7% YoY

Gross Profit

$4M96.7% margin

Operating Income

-$18M-459.2% margin

Net Income

-$20M-502.4% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

-55.6%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$178M

Total Liabilities

$94M

Stockholders' Equity

$84M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$9M	-56.7%
Gross Profit	$4M	$7M	-42.4%
Operating Income	-$18M	-$8M	-118.1%
Net Income	-$20M	-$5M	-334.0%